![]() Jefferies Financial Group reduced their price target on shares of Charles River Laboratories International from $233.00 to $203.00 and set a “hold” rating on the stock in a research report on Tuesday, March 28th. Get Charles River Laboratories International alerts:Ī number of equities analysts have recently weighed in on CRL shares. 98.55% of the stock is currently owned by institutional investors and hedge funds. FourThought Financial LLC now owns 256 shares of the medical research company’s stock worth $50,000 after purchasing an additional 45 shares in the last quarter. Finally, FourThought Financial LLC boosted its position in shares of Charles River Laboratories International by 21.3% during the third quarter. Covestor Ltd now owns 174 shares of the medical research company’s stock worth $49,000 after purchasing an additional 87 shares in the last quarter. Covestor Ltd boosted its position in shares of Charles River Laboratories International by 100.0% during the first quarter. Gradient Investments LLC now owns 189 shares of the medical research company’s stock worth $41,000 after purchasing an additional 186 shares in the last quarter. ![]() Gradient Investments LLC boosted its position in shares of Charles River Laboratories International by 6,200.0% during the fourth quarter. ![]() Allworth Financial LP now owns 168 shares of the medical research company’s stock worth $37,000 after purchasing an additional 63 shares in the last quarter. Allworth Financial LP boosted its position in shares of Charles River Laboratories International by 60.0% during the fourth quarter. Concord Wealth Partners bought a new position in shares of Charles River Laboratories International during the fourth quarter worth $33,000. Several other large investors have also bought and sold shares of the business. Raymond James & Associates owned approximately 0.45% of Charles River Laboratories International worth $46,897,000 as of its most recent SEC filing. The firm owned 232,370 shares of the medical research company’s stock after buying an additional 8,653 shares during the period. ( NYSE:CRL – Get Rating) by 3.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). Raymond James & Associates boosted its holdings in Charles River Laboratories International, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |